Friends Pharma (Pvt.) Ltd.
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical manufacturer and marketer with nationwide distribution and export activity.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- 31-KM Ferozepur Road, Lahore, Pakistan
- Website
- friendspharma.com ↗
- Phone
- +92 42 35935121-23
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Artemose | Artemether | 40 mg | Tablet | 8's | 054198 | PKR 519.57 | PKR 64.95/tablet | Near median |
| Artemose | Artemether | 80 mg/mL | Injection | 6 x 1ml | 081271 | PKR 1,038.27 | PKR 173.05/mL | 8% below median |
| Artemose | Artemether | 80 mg/mL | Injection | 5 x 1ml | 081271 | PKR 944.68 | PKR 188.94/mL | Near median |
| Artemose | Artemether + Lumefantrine | 15 mg + 90 mg/5 mL | Dry suspension | 60ml | 084576 | PKR 411.32 | PKR 6.86/mL | 17% above median |
| Artemose Extra | Artemether | 80 mg | Tablet | 4's | 067945 | PKR 432.98 | PKR 108.25/tablet | Near median |
| Artisaf | Misoprostol | 50 mg | Tablet | 2 x 10's | 032507 | PKR 438.88 | PKR 21.94/tablet | 14% above median |
| Ascorbifen | Ascorbic acid | 500 mg | Tablet | 40's | 103355 | PKR 45.90 | PKR 1.15/tablet | 25% below median |
| Bactirol | Moxifloxacin | 400 mg | Tablet | 5's | 050141 | PKR 947.77 | PKR 189.55/tablet | Near median |
| Beclotrim | Clotrimazole + Dexamethasone | 10 mg + 4 mg | Cream | 5 gm Tube | 032525 | PKR 47.70 | PKR 9.54/g | No comparator |
| Bepronate | Betamethasone + Gentamicin | 0.5 mg + 1 mg | Cream | 15 gm Tube | 032524 | PKR 95.41 | PKR 6.36/g | 15% below median |
| Betamycin | Betamethasone + Gentamicin | 1 mg + 1 mg | Cream | 15 gm Tube | 032523 | PKR 47.70 | PKR 3.18/g | No comparator |
| C-Fend-250 | Ciprofloxacin | 250 mg | Capsule | 10's | 060316 | PKR 260.48 | PKR 26.05/capsule | Near median |
| C-Fend-500 | Ciprofloxacin | 500 mg | Capsule | 10's | 060313 | PKR 430.80 | PKR 43.08/capsule | Near median |
| Cipfen | Ciprofloxacin | 250 mg | Tablet | 10's | 038994 | PKR 255.85 | PKR 25.59/tablet | Near median |
| Cipfen | Ciprofloxacin | 500 mg | Tablet | 10's | 038995 | PKR 511.70 | PKR 51.17/tablet | 20% above median |
| Cipfen | Ciprofloxacin | 200 mg | IV infusion | 100mlx1's vial | 083116 | PKR 194.03 | — | No comparator |
| Cipfen-XR | Ciprofloxacin | 1 g | Tablet | 10's | 060321 | PKR 718.35 | PKR 71.84/tablet | Near median |
| Dermicon | Miconazole | 2% w/w | Cream | 10 gm Tube | 041601 | PKR 59.86 | PKR 5.99/g | 31% below median |
| Dermicon-HC | Miconazole + Hydrocortisone | 2% + 1% w/w | Cream | 10 gm Tube | 032521 | PKR 114.49 | PKR 11.45/g | 29% above median |
| Diaphage-1000 | Metformin | 1000 mg | Tablet | 5 x 10's | 067950 | PKR 137.77 | PKR 2.76/tablet | 34% below median |
| Diaphage-500 | Metformin | 500 mg | Tablet | 5 x 10's | 067948 | PKR 126.26 | PKR 2.53/tablet | 7% below median |
| Dilomet DS | Metronidazole + Diloxanide furoate | 500 mg + 400 mg | Tablet | 15's | 032520 | PKR 141.20 | PKR 9.41/tablet | Near median |
| Fefocin | Clarithromycin | 500 mg | Tablet | 10's | 054192 | PKR 875.80 | PKR 87.58/tablet | Near median |
| Fefocin | Clarithromycin | 250 mg | Tablet | 1 x 10's | 054232 | PKR 383.78 | PKR 38.38/tablet | 19% below median |
| Fetaxime | Cefotaxime | 250 mg | Injection | 1’s | 048891 | PKR 105.67 | PKR 105.67/vial/unit | Near median |
| Fetaxime | Cefotaxime | 500 mg | Injection | 1’s | 048892 | PKR 159.25 | PKR 159.25/vial/unit | Near median |
| Fetaxime | Cefotaxime | 1 g | Injection | 1’s | 048893 | PKR 286.43 | PKR 286.43/vial/unit | Near median |
| Fledonil | Tranexamic acid | 500 mg | Injection | 5mlx10's | 090119 | PKR 1,615.68 | PKR 32.31/mL | 44% above median |
| Flufend | Fluoxetine | 20 mg | Capsule | 10's | 044757 | PKR 127.93 | PKR 12.79/capsule | Near median |
| Freclomide | Metoclopramide | 10 mg | Injection | 2ml x 10 | 071331 | PKR 393.62 | PKR 19.68/mL | 8% above median |
| Freingesic | Paracetamol + Codeine | 500 mg + 15 mg | Tablet | 10x10's | 060315 | PKR 566.72 | PKR 5.67/tablet | 43% above median |
| Frelexin | Cephalexin | 125 mg/5 mL | Suspension | 60 ml | 032538 | PKR 116.12 | PKR 1.94/mL | Near median |
| Frelexin | Cephalexin | 125 mg/1.25 mL | Oral drops | 10 ml | 032539 | PKR 150.40 | PKR 15.04/mL | No comparator |
| Frelexin | Cephalexin | 500 mg | Capsule | 2x6's | 032540 | PKR 393.62 | PKR 32.80/capsule | 7% above median |
| Frelexin | Cephalexin | 250 mg/5 mL | Suspension | 60 ml | 043708 | PKR 200.74 | PKR 3.35/mL | Near median |
| Frendpam | Diazepam | 2 mg | Tablet | 3x10's | 060764 | PKR 29.52 | PKR 0.98/tablet | 28% above median |
| Frendpam | Diazepam | 2 mg | Tablet | 1000’s | 060764 | PKR 196.80 | PKR 0.20/tablet | 78% below median |
| Frendpam | Diazepam | 5 mg | Tablet | 3x10's | 060765 | PKR 59.04 | PKR 1.97/tablet | 47% above median |
| Frendpam | Diazepam | 5 mg | Tablet | 1000 | 060765 | PKR 393.62 | PKR 0.39/tablet | 71% below median |
| Fri-Cin | Azithromycin | 250 mg | Capsule | 6's | 054196 | PKR 305.28 | PKR 50.88/capsule | Near median |
| Fri-Cin | Azithromycin | 250 mg | Capsule | 10's | 054196 | PKR 508.80 | PKR 50.88/capsule | Near median |
| Fri-Cin | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 060317 | PKR 329.23 | PKR 21.95/mL | Near median |
| Fri-Cin | Azithromycin | 500 mg | Tablet | 6's | 111655 | PKR 370.20 | PKR 61.70/tablet | 27% below median |
| Fri-Cin | Azithromycin | 250 mg | Tablet | 6's | 111656 | PKR 201.93 | PKR 33.66/tablet | 29% below median |
| Friclov | Aciclovir | 250 mg | Lyophilized injection | 1's | 099856 | PKR 721.54 | PKR 721.54/vial/unit | Near median |
| Friclov | Aciclovir | 500 mg | Lyophilized injection | 1's | 099857 | PKR 1,202.57 | PKR 1,202.57/vial/unit | 23% above median |
| Friebendazole | Albendazole | 200 mg | Tablet | 2's | 054230 | PKR 33.46 | PKR 16.73/tablet | 8% above median |
| Friebendazole | Albendazole | 200 mg | Tablet | 1 x 10's | 054230 | PKR 153.51 | PKR 15.35/tablet | Near median |
| Friedine | Ranitidine | 150 mg | Tablet | 1 x 10's | 054240 | PKR 110.21 | PKR 11.02/tablet | Near median |
| Friedine | Ranitidine | 50 mg/2 mL | Injection | 2ml | 076960 | PKR 37.39 | PKR 18.70/mL | 49% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.